爱尔兰爵士制药的去纤苷进医保了吗？

It was first developed by Gentium Pharmaceuticals in Italy and was approved for marketing in the EU in October 2013. After Gentium Pharmaceuticals was acquired by American Jazz Pharmaceuticals, Defibrotide sodium was approved by the U.S. Food and Drug Administration (FDA) to be launched in the United States on March 30, 2016, under the trade name Defitelio.

It is understood that the price of Defibrotide, a drug owned by Irish Jazz Pharmaceuticals, is around $22,000, and the specification is 200mg. Since this drug has not yet been approved for marketing in China, patients currently cannot buy this drug in China, so defibrotide cannot be included in medical insurance. Fortunately, patients can obtain their overseas drug purchase channels through reliable overseas medical service organizations in China (such as Medical Companion Travel). For patients, it is particularly necessary to grasp the timing of treatment, otherwise the condition may worsen.

Defibrotide can be administered both intravenously and orally, with the recommended dose for adult and pediatric patients being 6.25 mg/kg given every 6 hours as a 2-hour intravenous infusion. The dose should be based on the patient's baseline weight, which is defined as the patient's weight before the HSCT preparation protocol. Defibrotide was administered for a minimum of 21 days. If signs and symptoms of hepatic VOD have not resolved after 21 days, continue defibrotide until resolution of VOD or up to a maximum of 60 days. Defibrotide must be diluted prior to infusion.

Irish Jazz Pharmaceuticals is a commercial-stage biopharmaceutical company engaged in the identification, development and commercialization of pharmaceutical products. Since its founding in 2003, it has built a commercial and development organization and assembled products and product candidates that currently include two commercially available products, as well as product candidates in various stages of clinical development. As a drug under Irish Jazz Pharmaceuticals, it is worthy of patients' trust.

Recommended hot articles: /newsDetail/90892.html